Home›OB/GYN & Women's Health› Peptide therapies may restore fertility after TRT suppression, but evidence is limited
Peptide therapies may restore fertility after TRT suppression, but evidence is limitedNew peptide therapies may help men with low testosterone and fertility
Frontiers in MedicinePublished August 14, 2026DOI ↗Editorial oversight: Dr. Sofia Müller, MD · Lifespan & Whole-Person Care
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider peptide therapies as investigational; evidence for restoring fertility after TRT is limited.
This narrative review summarizes emerging peptide and neuroendocrine strategies for male hypogonadism, focusing on kisspeptin-based therapies, GnRH-related approaches, and neurokinin signaling pathways. The scope is to explore how these agents might activate the hypothalamic-pituitary-testicular (HPT) axis, potentially addressing reproductive suppression induced by testosterone replacement therapy (TRT).
The authors note that peptide-based therapies may support endogenous hormonal signaling through targeted activation of the HPT axis. However, they emphasize that direct evidence for restoration of spermatogenesis or fertility following TRT-induced suppression remains limited. No pooled effect sizes or quantitative outcomes are reported.
The review acknowledges several limitations, including limited direct evidence for key outcomes and unresolved questions regarding long-term efficacy, safety, treatment protocols, and patient selection. Adverse events and tolerability are not reported.
For clinicians, these emerging therapeutics may expand future treatment options for selected patients, but well-designed clinical studies are required before clinical use. This review should be interpreted as a preliminary overview, not a basis for changing practice.
How this fits prior evidence
This narrative review extends prior coverage by addressing a gap in reproductive management for hypogonadal men on TRT. While a prior meta-analysis linked TRT to increased fracture risk, this review explores strategies to mitigate TRT-induced reproductive suppression. It also complements a review on secondary osteoporosis and a systematic review on testosterone monitoring, by focusing on HPT axis activation. However, unlike the meta-analysis on docetaxel, this review provides no quantitative effect estimates, and its conclusions are qualitative and preliminary.
When men use testosterone replacement therapy, it can sometimes cause their bodies to stop producing sperm. This creates a difficult choice between managing hormone levels and maintaining the ability to have children. Researchers are now looking closely at peptide therapies as a potential way to balance these needs.
These treatments focus on specific signaling pathways in the body. They aim to activate the hormonal system naturally rather than just replacing hormones directly. While these methods show promise for supporting internal signaling, there is currently limited direct evidence showing they can successfully restore sperm production or fertility after it has been suppressed by treatment.
Because this research is still early, many questions remain about long-term safety and exactly which patients will benefit the most. These therapies represent a promising path for future options, but more large-scale clinical studies are needed to confirm how they work in everyday practice.
What this means for you:
Peptide therapies may help men maintain fertility while on testosterone, but more research is needed.
Common questions
Can these new peptides help my fertility?
These peptide-based therapies aim to support your body's natural hormonal signaling. While they may offer a way to manage reproductive health, there is currently limited direct evidence showing they can restore sperm production or fertility once it has been suppressed by testosterone treatment.
How do these treatments work differently?
Instead of just replacing hormones, these therapies focus on specific pathways like kisspeptin and GnRH-related approaches. They are designed to activate your body's internal hormonal system to help maintain balance.
Is this treatment safe for long-term use?
Because this research is still in the early stages, many questions remain regarding long-term safety, specific treatment protocols, and how different patients will respond. You should talk to your doctor about these emerging options.
The growing burden of male hypogonadism has raised concerns regarding the potential impact of modern lifestyles and environmental exposures on male reproductive health. Testosterone replacement therapy (TRT) is widely used for the treatment of male hypogonadism. However, prolonged TRT may suppress the hypothalamic-pituitary-testicular (HPT) axis, resulting in reduced gonadotropin production, decreased intratesticular testosterone levels, impaired spermatogenesis, testicular atrophy, and compromised fertility. Current management strategies, including human chorionic gonadotropin (hCG), follicle-stimulating hormone (FSH), and selective estrogen receptor modulators (SERMs), can support recovery in some patients, but their effectiveness remains variable. This narrative review examines the emerging role of peptide and neuroendocrine strategies in TRT-induced reproductive suppression and functional male hypogonadism. A structured literature search was conducted to identify experimental, translational, and clinical studies investigating reproductive peptides and related neuroendocrine pathways. Particular attention was given to kisspeptin-based therapies, gonadotropin-releasing hormone (GnRH)-related approaches, neurokinin signaling pathways, and other developing interventions with potential relevance to male reproductive health. Current evidence suggests that peptide-based therapies may support endogenous hormonal signaling through targeted activation of the HPT axis. However, direct evidence demonstrating restoration of spermatogenesis or fertility following TRT-induced suppression remains limited, and important questions regarding long-term efficacy, safety, treatment protocols, and patient selection remain unresolved. Emerging peptide therapeutics represent a growing area of interest in reproductive endocrinology and may expand future treatment options for selected patients. Nevertheless, further well-designed clinical studies are required to establish their long-term efficacy, safety, and role in restoring reproductive function following TRT-induced suppression.
